Robert Arathoon, PHD

Co-founder and CEO of Kenjockety since its inception in 2017. Prior to Kenjockety, Rob helped pioneer the development of ADC therapeutics targeting cancer stem cells at Stemcentrx (acquired by Abbvie). Over 22 years at Genentech, Rob held various leadership roles, including VP of Process Sciences, leading manufacturing operations and leading the team that pioneered cell culture systems used for production and approval of the first human biologics manufactured using Chinese Hamster Ovary (CHO) cells. Rob and colleagues pioneered the use of common light chain methods for bispecific antibody generation. Rob has presented at numerous international conferences, has published several papers, holds several patents, and received the 2006 Merck Cell Culture Engineering award. Rob holds a B.Sc in Biochemistry & Physiology, an M.S in Industrial Microbiology and a Ph.D. in Mammalian Cell Culture and Virology from the University of London.